Literature DB >> 9374368

Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells.

E Fonsatti1, M Altomonte, S Coral, I Cattarossi, M R Nicotra, A Gasparollo, P G Natali, M Maio.   

Abstract

Levels of circulating soluble intercellular adhesion molecule-1 (sICAM-1) are elevated in patients affected by solid malignancies; however, the cellular sources generating high levels of sICAM-1 remain to be characterized. Using conditioned media (CM) from seven ICAM-1-positive or -negative neoplastic cells, we demonstrate that tumour-derived interleukin 1alpha (IL-1alpha) significantly (P < 0.05) up-regulates the release of sICAM-1 by human umbilical vein endothelial cells. The intensity of the effect correlated with the amounts of IL-1alpha detectable in CM. Levels of ICAM-1 mRNA were also up-regulated by tumour-secreted IL-1alpha. The up-regulation of the shedding of sICAM-1 and of its expression at protein and mRNA level were completely reversed by the addition of anti-IL-1alpha neutralizing antibodies. Consistent with the in vitro data, tumour endothelia were strongly stained for ICAM-1 compared with autologous normal tissue endothelia. Taken altogether, our observations reveal an IL-1alpha-mediated tumour-endothelium relationship sustaining the shedding of sICAM-1 by endothelial cells. This is a general phenomenon in solid malignancies that correlates with the ability of neoplastic cells to secrete IL-1alpha rather than with their expression of ICAM-1 and/or histological origin. sICAM-1 has been previously shown to inhibit LFA-1/ICAM-1-mediated cell-cell interactions; therefore, the ability of neoplastic cells to secrete IL-1alpha is likely to represent a mechanism for their escape from immune interaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374368      PMCID: PMC2228138          DOI: 10.1038/bjc.1997.545

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma.

Authors:  M Altomonte; F Colizzi; G Esposito; M Maio
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

Review 2.  Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins.

Authors:  M R Ehlers; J F Riordan
Journal:  Biochemistry       Date:  1991-10-22       Impact factor: 3.162

3.  Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro.

Authors:  F J Burrows; D O Haskard; I R Hart; J F Marshall; S Selkirk; S Poole; P E Thorpe
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

4.  A form of circulating ICAM-1 in human serum.

Authors:  R Rothlein; E A Mainolfi; M Czajkowski; S D Marlin
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

5.  Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders.

Authors:  R Seth; F D Raymond; M W Makgoba
Journal:  Lancet       Date:  1991-07-13       Impact factor: 79.321

6.  Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases.

Authors:  M Tsujisaki; K Imai; H Hirata; Y Hanzawa; J Masuya; T Nakano; T Sugiyama; M Matsui; Y Hinoda; A Yachi
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

7.  Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue.

Authors:  M E Smith; J A Thomas
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

8.  Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; M Altomonte; A Gloghini; E Fonsatti; S Coral; A Gasparollo; R Montagner; I Cattarossi; C Simonelli; A Cattelan
Journal:  Int J Cancer       Date:  1995-05-16       Impact factor: 7.396

9.  Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders.

Authors:  M Maio; A Pinto; A Carbone; V Zagonel; A Gloghini; G Marotta; D Cirillo; A Colombatti; F Ferrara; L Del Vecchio
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

10.  Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro.

Authors:  F Vánky; P Wang; M Patarroyo; E Klein
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more
  5 in total

Review 1.  Intercellular adhesion molecule 1: recent findings and new concepts involved in mammalian spermatogenesis.

Authors:  Dolores D Mruk; Xiang Xiao; Marta Lydka; Michelle W M Li; Barbara Bilinska; C Yan Cheng
Journal:  Semin Cell Dev Biol       Date:  2013-08-11       Impact factor: 7.727

2.  Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells.

Authors:  Girish C Mohan; Huayi Zhang; Lei Bao; Benjamin Many; Lawrence S Chan
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 3.  The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment.

Authors:  Dolores Aguilar-Cazares; Rodolfo Chavez-Dominguez; Mario Marroquin-Muciño; Mario Perez-Medina; Jesus J Benito-Lopez; Angel Camarena; Uriel Rumbo-Nava; Jose S Lopez-Gonzalez
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-22       Impact factor: 6.055

Review 4.  Stromal regulation of embryonic and postnatal mammary epithelial development and differentiation.

Authors:  Beatrice A Howard; Pengfei Lu
Journal:  Semin Cell Dev Biol       Date:  2014-01-17       Impact factor: 7.727

Review 5.  Adhesion in Physiological, Benign and Malignant Proliferative States of the Endometrium: Microenvironment and the Clinical Big Picture.

Authors:  Emily J Rutherford; Arnold D K Hill; Ann M Hopkins
Journal:  Cells       Date:  2018-05-16       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.